{"entity":{"id":"gv20-therapeutics","kind":"company","name":"GV20 Therapeutics","aka":["GV20 Therapeutics"],"tldr":"GV20 Therapeutics is a US-based biotechnology company that leads 2 cancer trials in OnCo, testing the anti-IGSF8 antibody GV20-0251 in endometrial cancer, head and neck squamous cell carcinoma, melanoma and non-small-cell lung cancer.","summary":"GV20 Therapeutics is a clinical-stage biotechnology company that uses its AI-driven STEAD platform, combining B-cell repertoire data, omics data and disease biology, to discover antibody targets and therapeutics. Its lead candidate GV20-0251 is a first-in-class antibody against the immune checkpoint IGSF8, in phase 1 in the United States and China. On ClinicalTrials.gov it is the lead sponsor of 2 trials recorded in OnCo: NCT05669430 (phase 1/2, A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Par...) and NCT07070518 (phase 1/2, Study of GV20-0251 in Participants With Solid Tumor Malignancies). Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.","asOf":"2026-09-17","links":[{"label":"Official website","url":"https://gv20tx.com"},{"label":"ClinicalTrials.gov: trials led by GV20 Therapeutics","url":"https://clinicaltrials.gov/search?lead=GV20%20Therapeutics"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["endometrial","head-and-neck","melanoma","nsclc","hcc","sclc"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct05669430","nct07070518"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo orphan-trial linking round (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-17"},"hq":"Newton, Massachusetts","country":"US","companyType":"biotech","website":"https://gv20tx.com","stage":"startup","investors":[],"funding":[]},"route":"/companies/gv20-therapeutics/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"hcc","kind":"cancer","name":"Hepatocellular carcinoma","route":"/cancers/hcc/"},{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"nct05669430","kind":"trial","name":"A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies","route":"/trials/nct05669430/"},{"id":"nct07070518","kind":"trial","name":"Study of GV20-0251 in Participants With Solid Tumor Malignancies","route":"/trials/nct07070518/"}]}}